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Abstract: Acquisition of resistance is one of the major causes of failure in therapy of bacterial infections. According to 
the World Health Organization (WHO), thousands of deaths caused by Salmonella sp., Escherichia coli, Staphylococcus 
aureus or Mycobacteria tuberculosis are due to failure in therapy caused by resistance to the chemotherapeutic agents. 
Understanding the mechanisms of resistance acquisition by the bacterial strains is therefore essential to prevent and over-
come resistance. However, it is very difficult to extrapolate from in vitro studies, where the variables are far less and un-
der constant control, as compared to what happens in vivo where the chosen chemotherapeutic, its effective dose, and the 
patient’s immune system are variables that differ substantially case-by-case. The aim of this review is to provide a new 
perspective on the possible ways by which resistance is acquired by the bacterial strains within the patient, with a special 
emphasis on the adaptive response of the infecting bacteria to the administered antibiotic. 
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INTRODUCTION 
 Resistance to antibiotics represents a worldwide health-
care problem that affects therapy of infectious diseases 
caused by a large variety of organisms including Gram-
negative, Gram-positive bacteria or mycobacteria. Since the 
discovery of penicillin, antibiotics and other antimicrobial 
agents have been successfully employed for treatment of 
infections. On the other hand, traditional medicine, which is 
probably as old as mankind, has been extensively used in a 
wide variety of applications. Within tribal communities, 
various plants, fungi and even animal body parts have com-
monly been ingested or topically applied with a therapeutic 
aim for various diseases including infections [1]. Traditional 
Chinese medicine is an excellent example of a complex 
therapeutic system that has a strong focus on natural prod-
ucts and provided valuable subjects also for chemistry-based 
drug discovery [2-4]. 
 Development of antibiotic resistance by a bacterial strain 
is most typically due to antibiotic misuse consequentially 
leading to an ineffective therapy [5, 6], which, for example, 
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in economically disadvantaged countries can also occur due 
to inadequate access to drugs [7]. Bacterial resistance has 
been detected for all classes of antibiotics [8] and with re-
spect to a wide variety of infections including those caused 
by Escherichia coli, Salmonella sp., Staphylococcus aureus 
or Mycobacterium tuberculosis, resistance to one or more 
antibiotics has become a commonplace issue [9]. Excellent 
and extensive reviews that cover different mechanisms of 
resistance including modulation of porins [10-12], efflux 
pumps (EPs) [13-15], and lipopolysaccharide components of 
the cell wall [16] have been published and characterization 
of these mechanisms will not be the main focus here. Instead 
of that, this review aims to discuss possible relationships 
between environmental conditions and the mechanisms of 
resistance developed by bacterial strains during infection and 
therapy. 
ACQUISITION OF RESISTANCE 
 The process of resistance acquisition by the bacterial 
cells can apparently be divided into two major stages: 1) a 
first and fast response which includes the reorganization of 
the membrane and its permeability [17] (change in lipopoly-
saccharide composition [17], decrease of porin content [10-
12] and/or over expression of efflux pumps [13-15]), and 2) 
a second, slow response that would involve genetic changes. 
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Many of the possible genetic changes are not well described 
or completely understood, however, one may suppose that 
they would involve the acquisition of mutations, promoted 
for example by activation of “mutator genes” [18]. Other 
mechanisms may also determine the process of resistance 
acquisition, like horizontal gene transfer between organisms, 
or activation of cell signalling responses which are closely 
related to the behaviour of bacteria in the wild; bacterial 
communication (quorum sensing) [19-21] and biofilm for-
mation [22]. This latter phenomenon may also play an im-
portant role in bacterial pathogenicity and host colonization 
[23]. Nevertheless, it is almost sure that all these events are 
correlated and play an important role in the acquisition of 
resistance by a bacterial strain in a patient treated with anti-
biotics. 
1. Signalling Molecules 
 Adaptation of bacterial strains to the environment within 
the living organism before and/or after starting therapy has 
an undoubtedly close relationship with evolutionary proc-
esses [24, 25]. This is supported by many studies on the role 
of antibiotics and other molecules used by microorganisms 
as cell signalling agents, and by the responses of pathogenic 
bacteria to different stimuli [20, 26]. Interestingly, sub-
inhibitory concentrations of commonly used antibiotics were 
found to induce responses in the bacterial cell significantly 
different to those observed at greater concentrations [27, 28]. 
Moreover, response of bacteria to environmental changes has 
been described along with successful co-operation and co-
evolution among species [29, 30]. The role of natural antibi-
otics (firstly isolated from bacteria, fungi, plants, etc) was 
also studied in their original environment [31], and Linares 
and his co-authors suggested that antibiotics can also be in-
terpreted as signalling agents instead of “weapons” [32]. The 
generally accepted point of view, that these compounds are 
used by bacteria to fight competitors in their natural envi-
ronment [32] may completely be overwritten by the idea that 
antibiotics serve as signalling molecules and regulators of 
the homeostasis of the bacterial community [33], playing an 
important role in biofilm formation, symbiosis, etc. It was 
demonstrated that for example tobramycin, an antibiotic 
aminoglycoside produced by Streptomyces tenebrarius, can 
inhibit the quorum sensing (QS) system of an environmental 
Pseudomonas aeruginosa strain when applied at sub-
antibiotic concentrations [28].  
 In the bacterial genome the information for the biosyn-
thesis of antibiotics and other signalling molecules com-
pounds is usually present in clusters, which also contain ge-
netic information for activation of the so called resistance 
mechanisms and which are also common to several different 
signalling molecules [26]. The information present in such 
gene clusters can than pass among bacteria either vertically 
(generation through generation of a bacterial species) or 
horizontally (between species) [25].  
 It was shown by Hosaka and co-authors that different 
bacterial strains known for producing several antibiotics con-
tain a larger pool of silent genes encoding a higher variety of 
antibiotics that can be biosynthesized by that specific bacte-
rial strain under certain conditions [34]. Presence of a simi-
larly large pool of silent resistance genes encoding all neces-
sary mechanisms for self-defence against all possible (evolu-
tionary already “invented”) endogenous antibiotics seems to 
be a logical consequence of this; however to our knowledge 
such studies have not been extensively connected with the 
specific mechanisms used by bacteria to acquire resistance. 
2. Reorganization of the Membrane and Its Permeability 
as a Response to Antibiotic Pressure  
2.1. Lipopolysaccharides (LPS) 
 Acquired resistance to antibiotics through a decrease in 
the permeability of the cell membrane requires major struc-
tural changes in the membrane [35-37]. However, due to the 
composition of the cell barrier, there is a general difference 
in the susceptibility to hydrophobic and hydrophilic com-
pounds [38]. Gram-negative bacteria have an extra “protec-
tion” given by the outer membrane. For this reason some 
antibiotics that are active against Gram-positives are not ac-
tive against Gram-negatives. LPS composition increases the 
asymmetry in the membrane architecture and the cross bind-
ing between LPS and divalent cations decrease permeability 
to hydrophilic agents [39].  
 Salmonella sp. is an example demonstrating the impor-
tance of LPS in virulence as well as intrinsic and acquired 
resistance to antibiotics [16, 39, 40], which shows well that 
LPS are more than a simple barrier: it is an essential part of 
the complex system responsible for the response of the bac-
terial strains to their environment. These systems are regu-
lated by host-derived signals that control gene expression for 
optimal establishment and maintenance of infection and acti-
vate virulence-factor expression, which allows the bacteria to 
survive, for example, within a neutrophil [16]. 
2.2. Porins 
 The regulation of membrane permeability in Gram-
negative bacteria is also a function of membrane proteins. 
Regulation involves the joint action of porins and efflux 
pumps. Porins, found in Gram-negatives and mycobacteria, 
are trimers of identical subunits, each consisting of an anti-
parallel -barrel forming a pore [41]. These proteins form 
channels that traverse the outer membrane and end in the 
periplasm. They serve as the main entry for different classes 
of antibiotics such as -lactams or fluoroquinolones, as well 
as a large variety of small hydrophilic molecules [42-45]. 
Indeed, some -lactam resistant strains of E. coli have shown 
a deficiency in the expression of the outer membrane protein 
(Omp) with alterations in its loop structure, caused by muta-
tions. This can interfere with the interaction of the antibiotic 
with the surface of the channel, which determines its pene-
tration inside the cell [45]. In fact, clinical isolates with 
modifications in the structure of their porins were already 
identified in many Gram-negative strains [12]. Moreover, 
porin-deficient mutants are also more resistant to quinolones, 
tetracyclines, chloramphenicol, nalidixic acid and 
trimethoprim [44]. P. aeruginosa has innate low susceptibil-
ity to -lactams due to its low porin content with distinct 
physicochemical properties as compared to other strains 
[12]. 
 It was also observed that the expression of OmpC and 
OmpF, controlled by the concentration of some antibiotics in 
the environment, regulates the permeability of the outer 
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membrane to glucose under nutrient deficient conditions 
[46]. Most of the related studies aimed to explore the mecha-
nisms involved in this. [45-48]. It was shown that some 
clinical isolates, obtained from patients undergoing treat-
ment, had their membrane permeability changed due to a 
switch in the expression of porins from OmpF to OmpC, 
which latter one has a smaller pore size. This modification in 
the porin balance was suggested to have occurred during the 
treatment [12]. OmpC-OmpF balance is strongly regulated 
by different genetic control systems, such as EnvZ-OmpR 
and RNA anti-sense regulators (MicF and MicC) [12, 49, 
50]. 
 Some in vitro studies also showed that loss of OmpC is 
followed by the expression of another subfamily of porins. 
OmpN type of porin is structurally related to OmpC and 
OmpF. OmpN pore is a selective filter for charged molecules 
due to its structural organization. It allows the maintenance 
of bacterial fitness with the entrance of nutrients but not an-
tibiotics. This increases the resistance to the -lactams [12]. 
OmpX is another important outer membrane protein: it is 
small, and, together with OmpF, it is involved in the re-
sponse to external stress via different regulation cascades 
[48]. 
2.3. Efflux Pumps (EP)  
 While porins represent entrances for compounds exoge-
nous to the bacterium, cellular efflux systems are responsible 
for the extrusion of both endogenous (e.g. toxic metabolites) 
and exogenous (e.g. bile salts) toxic compounds [13, 51, 52], 
playing an important role in the physiology and homeostasis 
of the cell [53]. Some EPs have also been shown to have a 
role in colonization and persistence of bacteria in the host, as 
well as in bacterial pathogenicity [53-56]. Moreover, EPs 
were shown to play an essential role in quorum sensing sig-
nalling between bacteria and in biofilm formation [13, 57]. 
EPs are also useful tools for the cell to remove antibiotics 
conferring resistance to a given drug or class of drugs [25, 
55, 58-61], as well as heavy metals, dyes or detergents [62]. 
Extensive reviews on the structure, classification, specifici-
ties and efflux kinetics of different EPs can be found in the 
literature, which will not be detailed here. 
Acquisition of resistance: overexpression of EP plus acqui-
sition of mutations? 
 Antibiotic therapy commonly results in the appearance of 
resistance of the infecting bacterium to the drug. Although a 
variety of mechanisms account for distinct forms of resis-
tance, the over-expression of efflux pumps extruding the 
antibiotics is a major mechanism in the resistance of clinical 
isolates [15, 58]. The tri-partite efflux pumps of Gram-
negative bacteria, for reasons yet to be completely under-
stood, have the capacity to recognize and extrude a wide 
variety of unrelated compounds such as antibiotics from dif-
ferent classes, biocides and other noxious agents like bile 
salts [13]. Based on this, over-expression of these EPs results 
in a multi-drug resistant (MDR) phenotype leading to serious 
difficulties in the therapy of an infection [63].  
 The mechanism by which these MDR efflux pumps are 
over-expressed has been studied in the laboratory; gradual 
and prolonged exposure of the bacteria to increasing antibi-
otic concentrations of the antibiotic that are just below its 
MIC promote the over-expression of individual efflux pumps 
consequentially leading to the increase of resistance to the 
actual antibiotic as well as to other non-related ones [46, 64, 
65]. Transfer of the now MDR phenotypic bacterium to drug 
free medium restores, over time, the initial susceptibility to 
the inducing antibiotic, as well as eliminates its MDR pheno-
typic status [46, 64]. Nevertheless, these studies do not en-
tirely explain how MDR phenotypes develop in a clinical 
setting, since therapy does not involve progressive increases 
of dose levels: a clinical isolate has never been exposed to 
the drug over the therapeutic dose. Furthermore, considering 
that the level of resistance of the MDR clinical isolate to a 
given antibiotic may be hundreds of times greater than that 
of its wild-type reference strain, it is difficult to reconcile 
simple laboratory studies that would induce high levels of 
resistance with continuous exposure to increasing concentra-
tions of an antibiotic. 
 It was shown that exposure of E. coli to stepwise increas-
ing amounts of tetracycline (TET) concentrations increases 
resistance to TET [64] that is accompanied by an increase of 
resistance to many other antibiotics and non-antibiotic 
agents, producing an MDR phenotype. This MDR phenotype 
is accompanied by significantly increased activity of genes 
encoding transporter proteins [64]. Similarly, exposure of 
isoniazid (INH)-sensitive M. tuberculosis to increasing con-
centrations of INH also increased the resistance of the organ-
ism to this antibiotic [66] but resistance to INH was not ac-
companied by resistance to any other drug employed for the 
therapy of pulmonary tuberculosis. These studies, however, 
did not completely mimic the conditions of exposure of a 
given bacterium to an antibiotic, which would occur when a 
patient, infected with this organism, is treated for a pro-
longed period of time with a constant dose of the antibiotic. 
 Other experiments, aiming a better simulation of the 
clinical conditions, showed that serial culture of an E. coli 
strain whose efflux pump had been over-expressed, in me-
dium containing a constant amount of the antibiotic to which 
the strain had been induced to high level resistance, results in 
the restoration of the activity of genes that regulate and code 
for the efflux pump transporters, as compared to those of the 
antibiotic susceptible E. coli strain [67]. Accompanying the 
restoration in these gene activities is the continuous increase 
of resistance to the antibiotic even though the bacterium had 
not been exposed to higher concentrations of the antibiotic to 
which it had been made resistant. This E. coli strain also 
displayed progressively increased resistance to compounds 
that target cell envelope constituents, gyrase and ribosomes, 
supporting the assumption that a large number of mutated 
targets emerged due to the continuous sub-culturing in the 
medium containing a constant concentration of an antibiotic. 
The inability of the obtained resistant E. coli strain to revert 
to the initial susceptibility to tetracycline or to the antibiotics 
that contributed to its MDR status when cultured further in a 
drug-free medium, as happened for its resistant E. coli paren-
tal strain [46], together with results from phenotypic array 
studies suggest that indeed mutations had taken place. 
 The maintenance of an over-expressed efflux pump sys-
tem must consume a large, yet undefined amount of energy: 
EPs driven by the proton motive force depend on metabolic 
energy as the main source of protons in order to assure the 
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pH gradient [68]. However, it is expected that bacterial sys-
tems tend to a low energy level (following the second law of 
thermodynamics). One may suppose that after exposure to an 
environment that remains noxiously constant, the genetic 
system of the organism responds by activation of a mutator 
system [18] resulting in the accumulation of mutations that 
render the organism multi-drug resistant. Although as long as 
the organism remains in that environment its survival is as-
sured, if the environment returns to that initially present, the 
organism cannot compete with its wild type counterpart 
which has all relevant biochemical targets fully functional.  
 The above study therefore demonstrates “evolution of a 
bacterial strain” within a laboratory environment, and may 
model the situation that takes place within a patient who is 
infected with a bacterium and is treated for a prolonged pe-
riod of time with a constant dose of a given antibiotic. More-
over, this study also demonstrated that, by ensuring rela-
tively short-term survival, an over-expressed efflux pump 
provides the opportunity by which other, less energy-
consuming mechanisms of resistance may ensue, which 
eventually makes efflux pump overexpression itself unneces-
sary. 
 In the first phase, the induced MDR phenotype is subject 
to reversal by common efflux pump inhibitors (EPIs). How-
ever, after further serial passages in presence of high concen-
trations of the antibiotic, the strain remains resistant and 
cannot revert to the wild phenotype anymore. These observa-
tions are possibly related to those demonstrating that 
whereas some MDR clinical isolates may yield a reduced 
resistance to a given antibiotic when an EPI is added to the 
medium, the EPI does not affect, or affect less, other clinical 
strains [69, 70]. It can be assumed that the efflux pump over-
expression represents the early response to prolonged ther-
apy with the same antibiotic either at the same or greater 
dose levels whereas the latter case represents a much later 
adaptive response. 
3. Future Perspectives 
 Multi-drug resistance in bacteria remains a problem yet 
to be fully understood. With this short review on fundamen-
tal ideas and research work we aimed to give a contribution 
to the overall solution to understand and overcome resistance 
of clinical strains to therapeutics in the patient. In fact, the 
solution is, most likely, not only one, and in no case uniform. 
It may vary strain by strain, since different bacterial species 
can show marginally different responses to antibiotic pres-
sure. Some develop resistance to that antibiotic, others resis-
tance to that and other antibiotics, others form biofilms and 
have increased QS signalling in presence of certain antibiotic 
concentration or the opposite, inhibition of QS signals in 
presence of an antibiotic can also occur. The overall signal-
ling role of antibiotics between strains is a very exciting the-
ory: in such a bacterial communication system, certain porins 
could be interpreted as “ears” (i.e. signal receivers), while 
efflux pumps would be the “mouth” (i.e. signal senders by 
extruding endogenous, biosynthesized “antibiotics”). Exis-
tence of such fine systems, supported by many studies, cer-
tainly has several other aspects of potential interest in view 
of fighting resistance, different to the approach of targeting 
porins or efflux pumps themselves. 
 In the clinical point of view many other factors, depend-
ing exclusively on the patient, also have to be taken into ac-
count, such as amount of drug delivered to the site of infec-
tion, metabolism, etc. 
 An approach that raised great hopes and has been studied 
for many years is that of finding compounds that inhibit the 
efflux pumps of bacterial cells leading to the increase in the 
intracellular concentration of the antibiotic so that it can 
reach the desired inhibitory concentration. However there is 
still much to do in this approach. Some of the compounds 
that were very promising in vitro showed high toxicity in 
vivo, due to their effect in the efflux pumps of human cells, 
such as those of the blood brain barrier. On the other hand, 
some promising compounds, such as certain phenothiazines 
(some of which are commonly used antipsychotic drugs), 
were able to cure patients with extremely drug resistant My-
cobacterium tuberculosis when applied at much lower con-
centrations than those considered toxic or psychoactive in 
humans [71-73]. Although these compounds were first de-
scribed as efflux pump inhibitors, their overall mechanism of 
action is probably other than a direct inhibition of the pump 
and is yet to be fully understood. It was however recently 
suggested, that phenothiazines actually target the host cell 
(macrophage), and enhance its killing capacity on the intra-
cellular pathogen [74, 75]. This group of compounds may 
hence provide valuable tools for exploring pathways that 
should be given priority for a more successful fighting 
against resistance with a new approach. 
 Many publications have visualized the end of the antibi-
otics’ era. Although, unfortunately, this point of view might 
indeed have a chance to be right, we do believe that, despite 
the great challenge, resistance can be overcome by utilizing 
the growing knowledge on novel possible target mecha-
nisms. 
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